Colorectal Cancer Clinical Trial
Official title:
Functional Recovery and Oncologic Efficacy of Robotic Versus Laparoscopy NOSE for Patients With Stage I III Left Sided Colon Cancer: A Randomized Controlled Trial
In this project, the investigator aims to provide the level 1 evidence for the comparison of robotic versus laparoscopic NOSE for the surgery of stage I-III colorectal cancer. the investigator hypothesize that, with the increased maneuverability of the current robotic system, robotic surgery will be a good option for patients with stage I-III colorectal cancer requiring a NOSE procedure.
Status | Recruiting |
Enrollment | 300 |
Est. completion date | October 6, 2025 |
Est. primary completion date | April 6, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Primary colon cancers located at the left sided colonic anatomic location, including distal transverse colon, colonic splenic flexure, descending colon, sigm oid descending colonic junction, sigmoid colon and upper rectum that required the mobilization of colonic splenic flexure to facilitate a curative resection and trans anal specimen extraction ; 2. TNM Stage I III adenocarcinomas; 3. Curative and elective surgery; 4. American Society of Anesthesiology (ASA) class I to III patients; 5. Age >18 years. Exclusion Criteria: 1. Cecal, ascending, the proximal and middle transverse colon cancers; and the middle or lower rectal cancers; 2. Emergency or palliative surgery; 3. Evidence of disseminated disease or adjacent organ invasion; 4. Primary tumor mass >8 cm in diameter; 5. Morbidly obese patients, that is, body mass index (BMI) =40 kg/m 2 ; 6. Previous major surgery of upper abdomen or pelvis |
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
National Taiwan University Hospital |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The surgical efficiency of both NOSE procedures | The operation time defined as the incision of wound and application of the surgical dressing | Intraoperative hours with an average of 5 hours | |
Secondary | Overall disease-free survival | The duration between surgery and death | 5 years | |
Secondary | Overall recurrence-free survival | The duration between surgery and recurrence | 5 years | |
Secondary | Incontinence | Evaluated by questionnaire | 6 months | |
Secondary | Time to return work | Disability | 1 year | |
Secondary | Total fee and equipment fee | Total Cost | 3 months | |
Secondary | Blood loss | measured by the amount Mof blood in suction bottle and the number of blood soaked gauzes | Intraoperative hours with an average of 5 years | |
Secondary | Conversion rate | Conversion from robotic surgery to laparoscopic surgery or open surgery | Intraoperative hours with an average of 5 years | |
Secondary | Complications | Any complication during or after surgery grading by Calvien -Dindo classification | 30 days | |
Secondary | Wound size | Total length of the wounds | Intraoperative hours with an average of 5 years | |
Secondary | Serum C reactive protein (CRP) | CRP could be an indicator of the severity of surgical stress. | Throughout the admission with an average of 7 days | |
Secondary | Erythrocyte sedimentation rate (ESR) | ESR could be an indicator of the severity of surgical stress. | Throughout the admission with an average of 7 days | |
Secondary | Blood lymphocyte counts | Blood lymphocyte counts could be an indicator of the severity of surgical stress. | Throughout the admission with an average of 7 days | |
Secondary | CD4+ to CD8+ ratio | CD4 to CD8 ratio could be an indicator of the severity of surgical stress. | ESR could be an indicator of the severity of surgical stress. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |